Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect
- 1 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 84 (1) , 71-80
Abstract
Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk. Inhibitors against FXIa or FXIIa have been extensively studied because of their low bleeding risk. However, whether these compounds produce synergistic effects has not yet been explored. In this study, analyses of activated partial thromboplastin time in combination with the FXIa inhibitor PN2KPI and the FXIIa inhibitor Infestin4 at different proportions were performed using the SynergyFinder tool identifying synergistic anticoagulation effects. Both an FeCl3-induced carotid artery thrombosis mouse model and a transient occlusion of the middle cerebral artery mouse model showed that the combination of PN2KPI and Infestin4, which are 28.57% and 6.25% of the effective dose, respectively, significantly prevents coagulation, and furthermore, dual inhibition does not cause bleeding risk.Keywords
This publication has 50 references indexed in Scilit:
- Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Bifunctional fusion protein targeting both FXIIa and FXIa displays potent anticoagulation effectsLife Sciences, 2022
- Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe AnticoagulationJournal of Medicinal Chemistry, 2021
- COVID-19 : coagulopathie et thromboseLa Revue de Médecine Interne, 2021
- Recent advances in the discovery and development of factor XI/XIa inhibitorsMedicinal Research Reviews, 2018
- Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis RiskCell, 2016
- Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitorsEuropean Journal of Medicinal Chemistry, 2016
- Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding RiskProgress in Cardiovascular Diseases, 2015
- Factor XI: Hemostasis, Thrombosis, and AntithrombosisThrombosis Research, 2012
- Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosisThrombosis Research, 2010